Gilead Sciences, Inc. (BIT:1GILD)

Market Cap	141.37B +21.2%
Revenue (ttm)	25.79B +3.5%
Net Income	7.99B +54.5%
EPS	6.38 +55.4%
Shares Out	n/a
PE Ratio	17.69
Forward PE	15.09
Dividend	2.03 (1.78%)
Ex-Dividend Date	Dec 12, 2025

Volume	n/a
Average Volume	58
Open	116.46
Previous Close	114.52
Day's Range	116.46 - 116.46
52-Week Range	82.79 - 132.70
Beta	0.40
RSI	47.76
Earnings Date	May 7, 2026

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an inj...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1987
• Employees: 17,000
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1GILD

Financial Performance

In 2025, Gilead Sciences's revenue was $29.44 billion, an increase of 2.40% compared to the previous year's $28.75 billion. Earnings were $8.51 billion, an increase of 1672.92%.

Financial numbers in USD